WEREWOLF THERAPEUTICS INC

HOWLNASDAQ

🏆 #3637 by market capEarnings Nov 3US Equity

$976.24▲ $25.09 (+2.57%)

Simulated price

1h—

24h▲ 2.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$19M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

0.9x

Cheap

Otter Score

Weak

No chart data available for HOWL.

Trading Snapshot

Day Range: $961.26 – $981.40
52-Week Range: $0.27 – $2.38
Volume: $3.17B
Avg Volume: $2.24B
Shares Outstanding: 48.6M
Next Earnings: Oct 6, 2026

Fundamentals Snapshot

Annual Revenue: $21M
Last Q Revenue: $21M
P/E Ratio: —
P/S Ratio: 0.9x
EPS (TTM): $-0.73
Dividend Yield: —

Why Investors Own HOWL

✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$21M▲ +56.6% YoY

Gross Margin (TTM)

62.9%▲ +2.0% YoY

Operating Income (TTM)

$2M▲ +56.6% YoY

Free Cash Flow (TTM)

$3M▲ +56.6% YoY

About WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

🦦